ITRM20050290A1 - Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. - Google Patents

Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.

Info

Publication number
ITRM20050290A1
ITRM20050290A1 IT000290A ITRM20050290A ITRM20050290A1 IT RM20050290 A1 ITRM20050290 A1 IT RM20050290A1 IT 000290 A IT000290 A IT 000290A IT RM20050290 A ITRM20050290 A IT RM20050290A IT RM20050290 A1 ITRM20050290 A1 IT RM20050290A1
Authority
IT
Italy
Prior art keywords
ngf
analgesics
inhibit
molecules
bond
Prior art date
Application number
IT000290A
Other languages
English (en)
Italian (it)
Inventor
Antonino Cattaneo
Sara Marinelli
Flaminia Pavone
Gabriele Ugolini
Original Assignee
Lay Line Genomics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lay Line Genomics Spa filed Critical Lay Line Genomics Spa
Priority to IT000290A priority Critical patent/ITRM20050290A1/it
Priority to CA002610596A priority patent/CA2610596A1/en
Priority to EP06756318.9A priority patent/EP1890726B1/en
Priority to MX2007015487A priority patent/MX2007015487A/es
Priority to KR1020087000315A priority patent/KR101486085B1/ko
Priority to US11/921,826 priority patent/US9688749B2/en
Priority to JP2008515384A priority patent/JP5730464B2/ja
Priority to AU2006256387A priority patent/AU2006256387B2/en
Priority to EP06756317A priority patent/EP1893234A2/en
Priority to PCT/IT2006/000426 priority patent/WO2006131951A2/en
Priority to NZ564071A priority patent/NZ564071A/en
Priority to PCT/IT2006/000427 priority patent/WO2006131952A1/en
Priority to CN2006800288760A priority patent/CN101277718B/zh
Priority to US11/921,398 priority patent/US8691221B2/en
Priority to HK09101888.4A priority patent/HK1121403B/xx
Priority to EP11188102A priority patent/EP2484380A1/en
Priority to CA2611433A priority patent/CA2611433C/en
Priority to DK06756318.9T priority patent/DK1890726T3/en
Priority to JP2008515383A priority patent/JP5133879B2/ja
Priority to RU2007147625/15A priority patent/RU2427387C2/ru
Publication of ITRM20050290A1 publication Critical patent/ITRM20050290A1/it
Priority to NO20080084A priority patent/NO20080084L/no
Priority to JP2012106277A priority patent/JP2012158604A/ja
Priority to JP2013037304A priority patent/JP2013151509A/ja
Priority to JP2014163809A priority patent/JP2014218513A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT000290A 2005-06-07 2005-06-07 Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. ITRM20050290A1 (it)

Priority Applications (24)

Application Number Priority Date Filing Date Title
IT000290A ITRM20050290A1 (it) 2005-06-07 2005-06-07 Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CN2006800288760A CN101277718B (zh) 2005-06-07 2006-06-07 作为长效止痛剂的能抑制NGF与TrkA受体的结合的分子
PCT/IT2006/000427 WO2006131952A1 (en) 2005-06-07 2006-06-07 Novel analgesic treatment with prolonged effect
MX2007015487A MX2007015487A (es) 2005-06-07 2006-06-07 Moleculas que son capaces de inhibir la union entre el factor de crecimiento de nervios y el receptor trka como analgesicos con efecto prolongado.
KR1020087000315A KR101486085B1 (ko) 2005-06-07 2006-06-07 연장된 효과를 가지는 진통제로서 ＮＧＦ와 ＴｒｋＡ리셉터 사이의 결합을 억제할 수 있는 분자
US11/921,826 US9688749B2 (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
JP2008515384A JP5730464B2 (ja) 2005-06-07 2006-06-07 延長効果をもつ新規鎮痛治療
EP06756318.9A EP1890726B1 (en) 2005-06-07 2006-06-07 Novel analgesic treatment with prolonged effect
EP06756317A EP1893234A2 (en) 2005-06-07 2006-06-07 MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
PCT/IT2006/000426 WO2006131951A2 (en) 2005-06-07 2006-06-07 MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
NZ564071A NZ564071A (en) 2005-06-07 2006-06-07 Use of an anti-NGF IgG4 isotype antibody for treating and/or preventing chronic pain
CA002610596A CA2610596A1 (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between ngf and the trka receptor as analgesics with prolonged effect
AU2006256387A AU2006256387B2 (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
DK06756318.9T DK1890726T3 (en) 2005-06-07 2006-06-07 New analgesic treatment with extended effect
HK09101888.4A HK1121403B (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between ngf and the trka receptor as analgesics with prolonged effect
EP11188102A EP2484380A1 (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
CA2611433A CA2611433C (en) 2005-06-07 2006-06-07 Novel analgesic treatment with prolonged effect using an anti-trka antibody
US11/921,398 US8691221B2 (en) 2005-06-07 2006-06-07 Analgesic treatment with prolonged effect
JP2008515383A JP5133879B2 (ja) 2005-06-07 2006-06-07 ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子
RU2007147625/15A RU2427387C2 (ru) 2005-06-07 2006-06-07 МОЛЕКУЛЫ, СПОСОБНЫЕ ИНГИБИРОВАТЬ СВЯЗЫВАНИЕ МЕЖДУ NGF И РЕЦЕПТОРОМ TrkA, В КАЧЕСТВЕ АНАЛЬГЕТИКОВ С ПРОЛОНГИРОВАННЫМ ЭФФЕКТОМ
NO20080084A NO20080084L (no) 2005-06-07 2008-01-07 Molekyler som er i stand til a hemme bindingen mellom NGF og TrkA-reseptoren som analgetika med forlenget effekt
JP2012106277A JP2012158604A (ja) 2005-06-07 2012-05-07 ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子
JP2013037304A JP2013151509A (ja) 2005-06-07 2013-02-27 延長効果をもつ新規鎮痛治療
JP2014163809A JP2014218513A (ja) 2005-06-07 2014-08-11 ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000290A ITRM20050290A1 (it) 2005-06-07 2005-06-07 Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.

Publications (1)

Publication Number Publication Date
ITRM20050290A1 true ITRM20050290A1 (it) 2006-12-08

Family

ID=37056613

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000290A ITRM20050290A1 (it) 2005-06-07 2005-06-07 Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.

Country Status (14)

Country Link
US (2) US8691221B2 (OSRAM)
EP (3) EP1890726B1 (OSRAM)
JP (5) JP5730464B2 (OSRAM)
KR (1) KR101486085B1 (OSRAM)
CN (1) CN101277718B (OSRAM)
AU (1) AU2006256387B2 (OSRAM)
CA (2) CA2610596A1 (OSRAM)
DK (1) DK1890726T3 (OSRAM)
IT (1) ITRM20050290A1 (OSRAM)
MX (1) MX2007015487A (OSRAM)
NO (1) NO20080084L (OSRAM)
NZ (1) NZ564071A (OSRAM)
RU (1) RU2427387C2 (OSRAM)
WO (2) WO2006131951A2 (OSRAM)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
MX2009006594A (es) * 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
MY161564A (en) 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
WO2009077993A2 (en) 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
AU2009211340B2 (en) * 2008-02-04 2013-09-12 Lay Line Genomics S.P.A. Anti-TrkA antibodies and derivatives thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CA2736864C (en) 2008-09-19 2020-10-13 Pfizer Inc. Stable liquid antibody formulation
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
HRP20140309T1 (hr) 2008-10-22 2014-05-09 Array Biopharma, Inc. SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
CN106336400A (zh) * 2008-12-08 2017-01-18 萌蒂制药国际有限公司 酪氨酸激酶蛋白受体拮抗剂
BRPI1008692B8 (pt) * 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
KR20120088550A (ko) * 2009-05-04 2012-08-08 애보트 리서치 비.브이. 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AR078254A1 (es) * 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
KR102015402B1 (ko) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
AU2012252152B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
PL3498732T3 (pl) 2011-05-06 2022-02-28 Zoetis Services Llc Przeciwciała przeciw czynnikowi wzrostu nerwów oraz sposoby ich otrzymywania i zastosowania
US20140170136A1 (en) 2011-05-06 2014-06-19 Nvip Pty Ltd. Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
US9580496B2 (en) 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
NZ732875A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
RS66303B1 (sr) 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
JP2015503592A (ja) * 2012-01-05 2015-02-02 ビーチ ツリー ラボ、インコーポレイテッド 神経成長因子の投与による疼痛処置方法
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
SG11201408037SA (en) * 2012-06-08 2015-01-29 Glenmark Pharmaceuticals Sa Humanized anti-trka antibodies with amino acid substitutions
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015120136A1 (en) 2014-02-05 2015-08-13 VM Oncology LLC Compositions of compounds and uses thereof
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
JP6914834B2 (ja) 2014-11-16 2021-08-04 アレイ バイオファーマ インコーポレイテッド （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
BR112017015760A2 (pt) 2015-01-23 2018-03-27 Gvk Biosciences Private Limited inibidores de quinase trka
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
KR20180021745A (ko) 2015-06-01 2018-03-05 록쏘 온콜로지, 인코포레이티드 암을 진단하고 치료하는 방법
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
ES2987501T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Métodos de tratamiento de cánceres pediátricos
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
AU2017246554B2 (en) 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
PE20211707A1 (es) 2019-01-08 2021-09-01 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp
JP7671699B2 (ja) * 2019-05-30 2025-05-02 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 抗ＴｒｋＡ抗体及びその使用
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
EP4308101A1 (en) * 2021-04-21 2024-01-24 Redyneuheart S.r.l. N-acetyl cysteine for neuraxial use as a trka tyrosine kinase receptor inhibitor for the treatment of acute and chronic pain
IL311096A (en) * 2021-08-31 2024-04-01 Scout Bio Inc Antigen binding molecules and their uses
JP2025503539A (ja) 2021-12-28 2025-02-04 ４ビー テクノロジーズ（スーヂョウ） リミテッド ＴｒｋＡ抗体とその応用
EP4316481A1 (en) 2022-08-01 2024-02-07 Edmond Pharma S.R.L. Erdosteine, salts, enantiomers or metabolites thereof for use in the treatment of acute and chronic pain states
US20250122291A1 (en) 2023-10-13 2025-04-17 Cephalon Llc Anti-trka antibodies and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
WO1992008483A1 (en) 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
JPH06503722A (ja) 1990-11-30 1994-04-28 アボット・ラボラトリーズ 末端欠失神経成長因子受容体の検出に有用なイムノアッセイおよびモノクローナル抗体
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
EP0578515A3 (en) 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DE60044149D1 (de) 1999-08-06 2010-05-20 S I S S A Scuola Internaz Supe Transgene mäuse zur studierung von neurodegenerativen syndromen
WO2001052843A1 (en) * 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
HK1049184A1 (zh) 2000-03-16 2003-05-02 Genentech, Inc. 具有增强抗凝血效能的抗组织因子抗体
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US7507799B2 (en) * 2001-05-25 2009-03-24 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
EP2340849A1 (en) 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
AU2002324556A1 (en) * 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP3729841B2 (ja) * 2001-10-15 2005-12-21 麒麟麦酒株式会社 抗ｈｌａ−ｄｒ抗体の利用
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1556083B1 (en) * 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
ATE545429T1 (de) * 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
EP2270048B1 (en) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20040131515A1 (en) * 2003-01-03 2004-07-08 Alexanian Ara J. Material heat treatment system and method statement regarding federally sponsored research or development
WO2004065560A2 (en) 2003-01-18 2004-08-05 Rinat Neuroscience Corp. Methods of screening for modulators of nerve growth factor
KR20050111598A (ko) * 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
MEP31508A (hr) * 2003-07-15 2010-10-10 Amgen Inc Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade
WO2005044293A2 (en) 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7522822B2 (en) * 2004-01-06 2009-04-21 Robert Trujillo Halogen lamp assembly with integrated heat sink
AU2005243247B2 (en) * 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
EP2298345A3 (en) * 2005-01-24 2012-03-21 MedImmune Limited Specific binding members for NGF
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
MX2009006594A (es) * 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
MY161564A (en) * 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
WO2009077993A2 (en) 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
AU2009211340B2 (en) 2008-02-04 2013-09-12 Lay Line Genomics S.P.A. Anti-TrkA antibodies and derivatives thereof
CA2782712A1 (en) 2010-02-03 2011-08-11 Morinaga Milk Industry Co., Ltd. Method for manufacturing aloe powder
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions

Also Published As

Publication number Publication date
MX2007015487A (es) 2008-04-09
NO20080084L (no) 2008-03-07
US9688749B2 (en) 2017-06-27
JP5133879B2 (ja) 2013-01-30
HK1121403A1 (en) 2009-04-24
AU2006256387A1 (en) 2006-12-14
CA2610596A1 (en) 2006-12-14
US20100291083A1 (en) 2010-11-18
JP2008542440A (ja) 2008-11-27
JP2012158604A (ja) 2012-08-23
NZ564071A (en) 2011-07-29
CN101277718A (zh) 2008-10-01
US20090208490A1 (en) 2009-08-20
JP2014218513A (ja) 2014-11-20
WO2006131952A8 (en) 2008-01-10
EP1890726A1 (en) 2008-02-27
CA2611433A1 (en) 2006-12-14
EP2484380A1 (en) 2012-08-08
EP1890726B1 (en) 2014-11-19
JP2008542439A (ja) 2008-11-27
KR20080026593A (ko) 2008-03-25
AU2006256387B2 (en) 2011-12-15
JP5730464B2 (ja) 2015-06-10
WO2006131952A1 (en) 2006-12-14
RU2007147625A (ru) 2009-06-27
CA2611433C (en) 2016-11-08
US8691221B2 (en) 2014-04-08
CN101277718B (zh) 2011-12-21
EP1893234A2 (en) 2008-03-05
RU2427387C2 (ru) 2011-08-27
JP2013151509A (ja) 2013-08-08
DK1890726T3 (en) 2015-02-16
WO2006131951A3 (en) 2007-01-25
KR101486085B1 (ko) 2015-01-28
WO2006131951A2 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
HUE042689T2 (hu) TGFbéta elleni antitestek
CR10847A (es) Compuesto heteromonociclico y uso del mismo
PT1943264E (pt) Análogos de oligonucleosídeos incorporando neles 5-azacitosina
MA28989B1 (fr) MOLECULES Fc MODIFIEES
IL225372A0 (en) Antibodies directed to her-3 and uses thereof
DK1841920T3 (da) Ultrahøjstyrkeasfalt
EP1865042A4 (en) ANTIFREEZE
FR2876780B1 (fr) Structure de couplage
ITMI20050119A1 (it) Struttura di pannello e relativo procedimento di realizzazione
DE602006016400D1 (de) Damit
EP1889424A4 (en) MESSAGE TRANSMISSION IN PAGE MODE
FI20041503L (fi) Järjestely oskillointisylinterin yhteydessä
TR200505123A3 (tr) Çok fonksiyonlu birlestirme elemani
ITVR20050001U1 (it) Struttura di seggiolone
FIU20050132U0 (fi) Järjestely rakennenurkassa
ITMI20050667A1 (it) Vernice antivegetativa e suo uso
ITMI20050668A1 (it) Composizione verniciante procedimento per prepararla e suo uso
DE502006002465D1 (de) Höhenverstellbarer Querträger
UY3545Q (es) Configuración aplicada en licuadora
ITFR20050004U1 (it) Traliccio "conte" muniti di due piattinecon tondino distanziatore
FI6739U1 (fi) Repputeltta
ES1061725Y (es) Panel utilizado en la fabricacion de mobiliario
ITPD20050001U1 (it) Struttura di scrittoio
PT10032T (pt) Cinzeiro de praia